Coronavirus company news summary - Brazil suspends permit for import of Bharat Biotech vaccine - Rubic to develop Covid-19 vaccines for African market through licensing deal with Dyadic
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Coronavirus company news summary – Brazil suspends permit for import of Bharat Biotech vaccine – Rubic to develop Covid-19 vaccines for African market through licensing deal with Dyadic

28 Jul 2021

Brazil’s health agency Anvisa has provisionally suspended the permit for the import and supply of Indian firm Bharat Biotech’s Covid-19 vaccine in the country. Anvisa is seeking additional information on the vaccine including related technical and legal documents, Reuters reported. Last week, Bharat Biotech ended an agreement with its Brazilian partner Precisa to supply the vaccine in the country.

Dyadic International has entered into a Covid-19 vaccine technology transfer and licensing agreement with South Africa-based Rubic Consortium to discover, develop, assess and produce affordable vaccines for use mainly in the African markets. Rubic will gain a licence to Dyadic’s C1 Platform for research, development, regulatory approval and marketing of Covid-19 vaccines that may be produced in South Africa and sold in various countries on the African continent.

Florida-based infectious disease specialist Oragenics has signed a licensing agreement with the National Research Council of Canada (NRC) for the development of next-generation vaccines targeting the SARS-CoV-2 virus and its variants. The company will leverage its Terra CoV-2 vaccine to create cell lines for manufacturing spike protein antigens for current and emerging variants. The NRC will provide technologies to help accelerate preclinical and clinical studies of the antigen candidates.